Abstract Currently underutilized and in somewhat short supply, the pancreas allograft is a relatively scarce resource. Despite factors such as increased demand, positive changes in organ donation rates, and the liberalization of 'organ-acceptable' criteria, there has been a decline in the number of deceased donor pancreas transplants performed in the US. Concomitantly, there has been an increase in similar transplants performed in other countries. While it is understandable that there are a multiplicity of factors to be considered in the evaluation of the potential pancreas allograft donor in an attempt to minimize graft loss and morbidity, it is a simple truth that as a result there are unused transplantable organs. This paper will deal with the multifaceted problem of pancreas underutilization and will discuss strategies that could lead to the expansion of the pancreas donor pool.
Introduction
Given that donor organs are in critically short supply, the transplant community is challenged to make maximum use of all 'consented-deceased donor' organs. Recently, we have seen an increase in organ donation rates. Factors influencing this trend have been, among others, the expansion of the donor-acceptability limits, in particular with older and DCD (donation after circulatory death) donors. The systematic implementation of best practices has improved donor management and has increased conversion rates [1, 2] . Despite the fact that the concept of 'expanded criteria' exists in deceased donor kidney transplantation [3] , other solid organs, including the pancreas, do not benefit from the same guidelines.
In the US, the non-recovery rate among pancreata peaked at 81 % in 2011 [4••] . Deceased donor pancreas donation rates have steadily decreased since 2005, at which time the number of pancreata recovered peaked at 2,043. Furthermore, among recovered pancreata, the discard rate in the US increased from 10.8 % in 1998 to 27.7 % in 2011. This was due, in part, to strict criteria regarding the acceptability of a pancreas donor [2, 4••, 5••] . Different organ procurement organizations (OPOs) in the US report pancreas recovery rates varying from <5 % to 60-70 % of donors [2, [6] [7] [8] . This widespread variability in pancreas utilization can be explained by the consideration of the following factors [2, [6] [7] [8] [9] [10] . It is at the local level, rather than at the regional or national level, that we see the driving force behind pancreas transplantation. For this reason, the most potent predictor of local pancreas utilization is the establishment and maintenance of a strong and active local pancreas transplantation program, and this without reference to donor or logistical factors. Recent studies, however, report similar outcomes in imported, compared to local pancreas allografts. The one critical caveat is that cold ischemia times are kept below 12 hours [9] [10] [11] . In Eurotransplant, only 37 % of offered pancreata are transplanted and the discard rate among 'high quality' pancreata is 38 % [12] . Little doubt exists that there is profound underutilization of the pancreas; however, this well recognized phenomenon is incompletely understood because of the inconsistency of refusal rationales. Unfortunately, this leads to a significant number of 'avoidable' discards [12, 13] .
The fact that a donor is suitable for kidney, liver or heart donation generally indicates the same suitability for pancreas donation. Indications, contraindications, and risk factors for pancreas donation are listed in Table 1 . In general, traumainduced brain death, as opposed to cerebrovascular disease, would be preferable in the ideal donor. An age range of 10-40 years, accompanied by a 30-80 kg weight (body mass index [BMI] <27.5 kg/m 2 ) further underscores the criteria for the 'ideal' donor. Donor age, donor BMI, pancreas cold ischemia, and cause of death are probably the four most important factors determining pancreas organ suitability and transplant outcomes.
In this review, the problem of pancreas underutilization will be paired with strategies to expand the potential donor pool.
Contraindications to Organ Donation
Thankfully, organ donation is a field in which there are few absolute contraindications (Table 1) . One of the absolutes is the presence of active malignancy. Some primary brain tumors and non-melanoma skin cancers are exceptions to this rule. The presence of active malignancy, other than the aforementioned, would be definitive, because of concern for the transmission of malignant disease to the recipient of the transplant. Donors with long cancer-free survival, or who have undergone definitive therapy for malignancies, may represent a small, but acceptable risk for donor-transmitted malignancy [14] . For those recipients whose need for lifesaving transplantation (i.e., heart, liver, or lung) is immediate, or in patients that are either medically urgent (i.e., limited dialysis access) or have anticipated long waiting times (i.e., highly sensitized, blood type O or B), the benefits may outweigh the risks of disease transmission in kidney and pancreas transplantation. These donors, in general, are probably more appropriately passed over for pancreas procurement since pancreas transplantation does not normally fall into the 'lifesaving' category. Cancers that are understood to have high rates of early and/or [15, 16] .
Bacteremia, however, does not represent an absolute contraindication in pancreas donation. In the absence of sepsis, bacteremic donors rarely transmit infections and the current research indicates that outcomes of organs transplanted from such donors are similar to those from donors who are nonbacteremic [17, 18] . In order to minimize the risk of donorderived infection, it is standard practice to administer intravenous antibiotics to the transplant recipient for several days post-transplant to minimize the risk of donor-derived infection. This treatment would be directed specifically against the isolated donor organism. If the potential donor has a localized infection, the suitability of the pancreas for procurement is predicated upon the fact that it is uninfected or it is not in close proximity to or in direct contact with the nexus of infection. Because the pancreas is a retroperitoneal organ, 'open abdomen' or intra-abdominal infections are not, of necessity, contraindications to effective pancreas procurement and transplantation. Bacterial meningitis in a donor does not negate acceptability for pancreas donation, provided that the organism has been identified and the donor has been appropriately treated prior to organ recovery. Intravenous antibiotics are typically administered to the recipient for several days following transplantation; the treatment being identical to that used in the case of donor bacteremia, namely directed against the identified donor organism. The presence of viral meningitis or meningitis of unknown etiology in a donor, should, of course, be avoided due to an unacceptable and largely unknown risk of disease transmission to the recipient.
Donors with hepatitis C infection can be accepted, provided that their organs are transplanted into certain appropriate recipients with known hepatitis C. Donors with positive hepatitis B core antibody can provide acceptable organs for transplantation into recipients with positive hepatitis B surface antibody with a low risk of viral transmission. This is particularly effective if the donor is hepatitis B core antibody immunoglobulin M negative [19, 20] . Because solitary pancreas transplantation (SPT) is not considered directly lifesaving and because the waiting time for simultaneous kidneypancreas transplantation (SPKT) is usually shorter than for kidney transplant alone, it is considered more appropriate to delay the transplantation process until a donor with negative hepatitis serologies can be found. Human immunodeficiency virus (HIV), systemic viral infections and prion-related disease are currently considered absolute contraindications to organ donation. Testing for human T-lymphotropic viruses (HTLV I and II) is, in fact, no longer being performed in donors [21, 22] . Recent legislation in the US, however, may permit selective transplantation of organs from HIV-positive donors into appropriate HIV-positive recipients. This practice has been performed successfully in SPKT in other countries [23] .
As a final note, for reasons that are self-evident, donors with type 1 or type 2 diabetes mellitus are not appropriate candidates for pancreas donation. There are little to no data regarding pancreas donation from either non-diabetic donors with a history of gestational diabetes or donors with a history of obesity-related diabetes that resolved with weight loss. Transplanting pancreata from these donors, therefore, is inadvisable because the outcome would be unknown.
Risk Factors for Pancreas Donation
Donor considerations, such as age, BMI, and cause of brain death (in particular, death of a cerebrovascular origin), are considered critical determinants of pancreas transplant outcome. These factors can function as important determinants in the acceptance of pancreata for transplantation [5••] . As a result, the strict definition of what constitutes an acceptable pancreas donor remains a major factor in the underutilization and high discard rates of organs. More aggressive use of extended-criteria donors such as donors with a BMI >30 kg/ m 2 , aged <10 or >45 years, and DCD donors could potentially increase pancreas recovery and transplant rates, particularly in SPKT [24] . More liberal use of marginal donors, however, requires consideration of the potentially greater risks of technical failure and less-than-ideal outcomes against the significant morbidity and mortality of an extended wait for the 'ideal donor;' in particular, for patients with hyperlabile diabetes or end-stage diabetic nephropathy. There is a 'survival advantage,' of SPKT, and this would likely outweigh the greater risk of decreased pancreas graft survival in such cases. It could also provide a rationale for the more aggressive use of marginal donors. This would be significant, in particular, in patients with anticipated long waiting times [24] . Finally, a major determinant of pancreas transplant outcome is prolonged preservation time. This has limited broad sharing of pancreata across major geographic regions [9] [10] [11] . In an attempt to address the issue of more effective pancreas utilization, improved methods of communication and dissemination of donor information (such as with United Network for Organ Sharing [UNOS] DonorNet 2007) have been implemented in recent years. In order to facilitate organ sharing and reducing preservation time, transportation by charter aircraft may also play a role [25] .
If the donor age is greater than 45-50 years, donor BMI greater than 30 kg/m 2 , and there exists a cerebrovascular or non-traumatic cause of death, the risk for decreased pancreas graft survival is appreciably increased [5••] . Technical failure rates, and increased surgical complication rates are also linked to these factors. Registry data and large, single-center studies address the significance of these risk factors, and these will be discussed individually.
Donor Age
The technical complexity of the transplant operation can be influenced by extremes in age. Although frequently used for kidney transplantation, organs from very young donors may add the risk of very small vasculature and, therefore, a potential augmented risk for vascular thrombosis of the pancreas allograft. In older donors, the potential for vascular atherosclerotic disease in the graft itself may be a limiting factor. This is particularly true in the case of the vessels required for back table reconstruction. A Scientific Registry of Transplant Recipients (SRTR) study reviewed the cases of all deceased donor pancreas transplants from 2000 to 2003. The study showed lower pancreas graft survival rates in SPKT recipients of older donor organs (donor >50 years, 1 year: 76 %, 3 years: 56 %) when compared with SPKT recipients of younger donor organs (1 year: 86 %, 3 years: 78 %, p=0.04) [26] . These findings were confirmed in pancreas-after-kidney (PAK) recipients as well. A 2007 report from the Organ Procurement and Transplantation Network (OPTN)/SRTR summarized outcomes of kidney and pancreas transplantation in the US from 1996 to 2005. This study demonstrated 5-year pancreas graft survival rates of 60 % in recipients of donors older than 50 years compared with 73 % in recipients of donors aged 18-34 years [27] . Significantly lower pancreas graft survival rates in recipients of donors older than 45 years were reported in large, single-center studies from the University of Minnesota [28] and the University of Wisconsin [7] . As a result of the above data, a donor age greater than 45-50 years is generally considered to be contraindicated in pancreas transplantation. This is confirmed by the 2011 registry report demonstrating that the highest discard rate for pancreata recovered (81.3 %) was recorded from donors whose age was greater than 50 years [27] .
The age of the elderly donor is considered the single most important determinant of outcome in kidney transplantation and it remains an important impediment to the acceptance of any donor in pancreas transplantation. There is an increasing disparity between the availability of donor organs and the rate of demand. For the type 1 diabetic patient with renal failure, this creates a profound dilemma. Does one 'settle' for the older organs, a decision which might lead to a higher inherent risk, both of early graft failure or reduced graft longevity, when compared with organs from a younger donor, or does one wait for a more acceptable organ for transplantation, bearing in mind the inherent risk to the recipient, who may have to wait a longer time for surgery?
Many isolated pancreata from younger donors are available; however, they are underutilized because of the following factors.
& SPKT lists have been exhausted at the local level. & Paybacks affect the availability of the kidney; in addition, the kidney may not be available with the pancreas because of zero human leukocyte antigen (HLA) mismatch sharing, or combined transplantation with a liver or heart. & The degree of HLA match for the local SPT (or sensitized SPKT) recipient is inadequate. & There is no experienced local pancreas transplant team available.
Isolated pancreas sharing is relatively uncommon in the US, despite the availability of isolated pancreata from younger donors. Centers can be extremely selective with pancreas donors due to the fact that SPT waiting lists are usually small and waiting times are short. This applies not only with reference to donor age and quality but also with respect to HLA matching, geographic location, and procuring team. Acceptance criteria for SPKT donors tend to be more liberal because the waiting list is larger, waiting times are more extended, wait list mortality is higher, and posttransplantation outcomes are better, when compared with SPT. To add to this, even given the possible failure of the pancreas allograft, the patient receives a kidney transplant and dialysis is discontinued. The more favorable SPT waiting list can then be used so that the patient can receive a PAK transplant.
It is because of these issues that selected older donors (age >45-50 years) may be appropriate only for pancreas recovery in SPKT. The profile of an acceptable older donor for SPKT may include the following criteria. Vascular disease, pancreatic steatosis, and fibrosis are not necessarily predictable by older donor age alone. Patients with limited access to timely transplantation (for example, blood type O or B, highly sensitized) or those who cannot afford to wait for an extended period of time (unstable diabetes, prolonged duration of dialysis, older age [>50 years], advanced peripheral cardiovascular or vascular disease, limited dialysis access) represent the recipient population that is most likely to benefit from SPKT from older donors. In one study, a 72 % reduction in mortality was linked to patients receiving an SPKT from an older donor, as compared with remaining on the waiting list [29] . Because there is a continuing decline in the early allocation of organs from young donors, it has been suggested that receiving an SPKT from any age donor would be better than not receiving a transplant at all.
Conversely, a recent registry analysis of donor and recipient age in SPKT, using age 40 years as the cut-off for defining young versus old, demonstrated that on multivariable analysis, old donor SPKT was associated with significantly higher overall risks of patient death as well as death-censored pancreas and kidney graft failure in both young and old recipients [30] . Moreover, old donor SPKT resulted in reduced patient and graft survival without any waiting time benefit compared with young donor SPKT, except for candidates with expected long waiting times. In Eurotransplant, older donor age was identified as the only clinically significant factor differentiating between recovered pancreata that were transplanted (median donor age 31 years) or discarded (median donor age 42 years) [12] . In a recent, large, single-center, retrospective study, donor age >50 years, donor BMI ≥30 kg/m 2 , donor serum creatinine ≥2.5 mg/dL, and preservation time >20 hours were each identified as significant risk factors for early graft loss (within 90 days) secondary to technical failure in a multivariable Cox model, and were then used to create a composite risk model for predicting technical failure [31] .
Donor Obesity
Fatty pancreata, normally recovered from overweight donors, present issues for preservation and are technically more difficult to procure and to prepare on the back bench [32] . A recent review of pancreas transplant outcomes from the OPTN/SRTR database from 2000 to 2003 showed decreased 3-year pancreas graft survival rates in SPKT recipients of donors with a BMI >30 kg/m 2 compared with donors with a BMI ≤30 kg/m 2 (68 % vs 77.9 %, respectively, p=0.06). It is to be noted that the influence of donor BMI >30 kg/m 2 on pancreas graft survival was less pronounced than donor age >50 years [26] . The Minnesota group reported that a significantly higher technical failure rate was associated with a BMI , p=0.04). In addition, statistically higher rates of surgical complications were observed, in particular, surgical infections and thrombosis [33] . Recipients of pancreata from donors with a BMI >30 kg/m 2 experienced lower short-term graft survival rates; however, in technically successful transplants, the medium-term survival outcomes showed no significant differences between patients who had received pancreata from either obese or non-obese donors. This is consistent with the fact that the predominant cause of donor obesity-related graft failure is considered to be early technical failure. Multivariate analysis of risk factors for technical pancreas allograft failure in the Minnesota experience showed that a donor BMI >30 kg/m 2 had a relative risk of 1.7 (p=0.005). The higher fat content of the pancreas in obese donors gives rise to the likely association between that factor and surgical (wound and intra-abdominal) infection. Because this fat is poorly vascularized, it will be more prone to ischemia-reperfusion injury, fat necrosis, and inflammation, which can lead to peri-pancreatic fluid collections and allograft pancreatitis, and thus become a nidus for infection [34] . For these reasons, with only 11 % of all pancreata transplanted in the US recovered from donors with a BMI >30 kg/m 2 [24] , obese donors are typically avoided. A series that included 43 donors with a BMI >30 kg/m 2 was reported by Indiana University and found no significant differences in graft or patient survival, hospital length of stay, readmissions, or technical complications [35] . This study suggested that BMI is not always a reliable surrogate of fat content in the pancreas. Little or no fatty infiltration of the pancreas may be found in some overweight donors, while significant fatty infiltration of the pancreas may sometimes be found in some thin donors. In view of these findings, it becomes evident that the correlation is not absolute. Although there is little data available on biopsy-assessed pancreatic steatosis, the degree of fatty infiltration of the pancreatic parenchyma may correlate more appropriately with the degree of hepatic steatosis seen on liver biopsy. Even in the absence of obesity, significant pancreatic steatosis may be associated with a donor who has a history of excessive alcohol use. Fatty infiltration of the pancreatic parenchyma should, however, be distinguished from peripancreatic fat deposition. The latter is usually related to obesity, and is not uncommon, but is not of necessity associated with an adverse outcome.
Donor Cause of Death
High risks of technical failure are also associated with cerebrovascular or non-traumatic causes of donor brain death. The fact that a non-traumatic cause of brain death had a 1.58 relative risk of technical failure (p=0.04) compared with a traumatic cause of brain death was recently demonstrated by the Minnesota group [34] . These findings are similar to those of other contemporary studies [36, 37] . This is likely a reflection of underlying vascular disease, similar to that found in older donors, and is analogous to the lower graft survival rate normally associated with kidneys that have been recovered from donors who experienced a cerebrovascular cause of brain death.
DCD Donors
In recent years, organ use from DCD donors has increased. It should be noted, however, that pancreas transplantation from DCD donors has yet to gain widespread acceptance, and the proportion of DCD pancreas donors has remained relatively constant in the past 7 years in the US, at approximately 3.5 % of all pancreas donors [4••] . There is a growing literature, particularly in the United Kingdom, to suggest that DCD donor pancreas transplantation is certainly a viable option, although this should probably be reserved for otherwise ideal donors with a short cold ischemic time [38, 39, 40 ••, [41] [42] [43] [44] . There were only 57 pancreas transplants from DCD donors between 1993 and 2003 according to a review of US data [38] . Representing 0.1 % of all pancreas transplants, as of 2006, only 13 US centers had transplanted pancreata from DCD donors. In this series, 1-and 5-year pancreas graft survival rates in DCD donor recipients (85 % and 74 %, respectively) were comparable to pancreas graft survival rates in donationafter-brain-death (DBD) recipients (86 % and 70 %, respectively, p=NS), with a trend towards a higher thrombosis rate in DCD recipients (13 % DCD vs 6 % DBD, p=0.06). A higher rate of kidney delayed graft function (28 % DCD vs 8 % DBD, p<0.05) was seen in SPKT recipients of DCD donor organs. In a large, single-center experience, with SPKT from DCD donors, the University of Wisconsin group study reported similar 5-year pancreas graft survival rates in 37 DCD compared to 539 DBD donor groups (92 % DCD, 89 % DBD, p=0.18). There were no significant differences in infection rates, patient survival, thrombosis rates, and other functional outcomes [39] . It was not unexpected then, that in the DCD donor recipients, there was a higher incidence of kidney delayed graft function (24 % DCD vs 5 % DBD, p= 0.002). A more recent report from the UK compared the outcome of 134 DCD and 875 DBD pancreas recipients [44] . One-year pancreas and patient survival was similar between DCD and DBD, with pancreas graft survival significantly better in the DCD cohort if performed as an SPKT. Early thrombosis (8 % vs 4 %) was mainly responsible for graft failure in the DCD donor cohort.
Farney et al. [43] described a unique experience with four SPKTs, utilizing DCD donors. These donors were supported with extracorporeal membrane oxygenation in an attempt to minimize warm ischemic time and to achieve optimum organ function. Immediate kidney and pancreas graft function was evidenced in all four SPKT recipients with 100 % dual graft survival at a mean follow-up of 2 years. Warm ischemic time was minimized, following cardiac arrest, by the use of extracorporeal support in this small series. This obviated the need for rapid dissection of organs, thus potentially reducing the likelihood of surgical damage [45] . Large-scale applicability of this technique, however, may be limited by its need for additional resources and manpower.
In the absence of extracorporeal support or successful implementation of innovative preservation techniques such as normothermic perfusion, the warm ischemia inherent in the DCD organ donation process usually defines most DCD donors as 'marginal' for pancreas recovery because of concerns regarding ischemia-reperfusion injury resulting in allograft pancreatitis and culminating in early thrombosis. However, similar to the experience in liver transplantation from DCD donors, this characterization of donor quality may be inappropriate. With short periods of warm and cold ischemia in the setting of young, thin, otherwise stable individuals without aforementioned risk factors, excellent results can be obtained in DCD donor pancreas transplantation, particularly in SPKT.
Non-Standard Pancreas Donors
As a consequence of the previously mentioned known donor risk factors for poor outcomes, the 'ideal' pancreas donor may be defined as 10-40 years of age with a BMI <27.5 kg/m 2 ; this in addition to a non-cerebrovascular cause of brain death. Although transplanting pancreata from ideal donors may result in excellent outcomes, the obvious consequences will be the relative underutilization of deceased donor pancreata [46] . Only 13 % of all deceased donors in the US provided pancreata for transplantation in 2011 [2] . Pancreas donors do not benefit from a universally accepted definition for extended criteria like that found in kidney transplantation. This situation demands an ongoing reappraisal of the limits of acceptability when one considers pancreas offers from nonstandard donors. However, if one defines extended criteria as 'any donor who deviates from ideal criteria,' then the effective use of pancreata from marginal donors can be well described. Donors older than 45 years or hemodynamically unstable donors on highdose vasopressors were described as 'marginal' by Kapur et al. [47] . Actual graft survival rates were 86 % for the over-45 age group and 85 % for the hemodynamically unstable group. There was no difference in graft survival rates between donors who were marginal and those who were non-marginal. The importance of the inspection of the organ by an experienced pancreas transplant surgeon was emphasized by the authors. This was deemed to be more effective than restricting the use of grafts to factors such as age or hemodynamic status. Boggi et al. [48] also defined marginal pancreas donors as being older than 45 years and/or demonstrating hemodynamic instability. Again, comparable complication rates, graft survival, and patient survival were demonstrated with the utilization of both marginal and non-marginal donors. Other researchers have also reported successful outcomes with pancreata from older donors [37, 38, 49] . Singh et al. [50] defined 'extreme' pancreas donors as those <10 years or ≥45 years of age. This study also included those pancreata recovered from DCD donors managed with extracorporeal support. In this study, 24 % of SPKT recipients received extended-criteria donors over a 5-year period. Similar rates of actual pancreas graft survival were reported in recipients of extended-criteria donor organs (79 %) versus conventional (ideal) donors (80 %). These recipients also had comparable rates of infections, surgical complications, and acute rejection [50] .
Although there are data that show both superior and inferior outcomes with these donors, pancreata from young donors (<10 years) have also been considered extended criteria [24] . Etiologies for poor graft survival and higher technical failure rates have been implicated due to decreased islet mass and the small size of the splenic and superior mesenteric arteries in these pancreata. This perception is largely responsible for a general reluctance to utilize pancreata from young donors [51] . However, there are also reports of extremely effective outcomes with the use of pancreata from young donors. Oneand five-year pancreas graft survival rates of 92 % and 81 % were reported by a single-center review of 24 SPKT recipients from donors aged 4-10 years. This compared favorably to outcomes in recipients of pancreata from donors aged 18-45 years [7] . The largest series compared 538 recipients of adult donor organs with 142 SPKT recipients of pancreata from donors aged 3-17 years. The pancreas graft survival rate in the pediatric donor group (72 %) at 10-year follow-up was actually superior to the adult donor group (61 %, p=0.05) [52] . With recipients stratified according to donor age (<12 years vs age 12-17 years), there were no differences in graft survival rates; nor were there differences in leak rates or thrombosis between pediatric and adult donor recipients.
The authors suggest that excellent outcomes can be obtained using pancreata from pediatric donors, provided that the donor weighs more than 25 kg and is older than 3 years. There is a continuing evolution in lower age and body size limits for pancreas donation; however, as a technique, a successful pediatric en bloc SPKT from a 13-kg, 31-month-old child donor has been reported [53] .
Assessment of the Potential Pancreas Donor Prior to Recovery
Multiple factors influence the decision to transplant a pancreas allograft. Among these are [5••, 46] : & the donor history, presentation, and clinical course prior to procurement; & the appearance of the graft at the time of organ recovery; & ischemia time and issues related to preservation.
In the final analysis, it is a combination of such variables in the context of the recipient's history, the physiologic reserve of the recipient, and the expected degree of difficulty of the transplant procedure that direct the team to an appropriate decision. There are other additional aspects of the donor history that may play a role in the final decision to accept an organ for transplantation. Diabetes in the donor is generally accepted as prohibitive for pancreas transplantation. Similarly, a history of acute or chronic pancreatitis in the donor may render the pancreas unsuitable for transplantation. There is no doubt that a history of heavy alcohol consumption might be associated with acute or chronic pancreatitis. The pancreas, in many of these cases, particularly in young donors, may appear normal and function appropriately. It is advisable, therefore, in these instances, to await visualization before ruling out an organ from a donor with a history of alcohol abuse.
If performed recently for the same trauma that led to donor death, splenectomy is not necessarily a contraindication to pancreas transplantation.
In these cases, however, the graft will require close scrutinization for splenic vein thrombosis or for an injury to the tail of the organ.
Retroperitoneal hematoma following abdominal trauma in donors would indicate that a similar approach be employed. In this case, it would be of great importance to rule out injury to the graft parenchyma in the region of the neck of the pancreas (where the organ crosses the vertebral column) or to the duodenum of the donor. Prior to procurement, an abdominal computerized tomographic scan could be invaluable as a tool in determining suitability of the pancreas for transplantation.
Despite the fact that amylase, lipase levels, and serum glucose levels may be helpful in determining the quality of a pancreas allograft, there are other variables in the donor that may render these tests less useful. Strokes or brain injuries in donors may result in elevated serum glucose levels, secondary to relative insulin resistance. Brain edema protocols often demand the use of steroids. These, in conjunction with the administration of intravenous fluids high in dextrose content that are frequently used to correct hypernatremia and hypoglycemia, would also affect the utility of the previously mentioned serum levels. Intestinal injury or injury to the salivary glands in cases of head trauma can result in hyperamylasemia. Hyperlipasemia is more specific to the pancreas and should raise concern for pancreatic inflammation, injury, or edema. Progressive renal failure or elevation in liver enzymes may provide another indication that the pancreas may be compromised. The host OPO routinely provides the primary data required to determine whether a particular organ donor is suitable for an intended recipient (Table 2) .
Protocols regarding quantitative assessment of pancreas donor quality have now been put in place. These are seen as predictive of either pancreas donor utilization or graft failure. The Eurotransplant network has developed the PreProcurement Pancreas Suitability Score (P-PASS) as a composite score including [54, 55] 
Based upon clinical expertise and known literature, the above variables were accorded defined ranges and weighted points. Ideal donors were defined as a P-PASS <17, using pancreas acceptance as an outcome variable. This was based on a multiple regression analysis that identified donors with a P-PASS ≥17 as more than three times as likely to be refused for pancreas utilization. A Pancreas Donor Risk Index (PDRI) based on ten donor variables (donor gender, age, black and Asian race, BMI, height, cause of death, serum creatinine level, and DCD status) and one transplant variable (ischemia time) was developed. This was effected by performing a retrospective Cox regression analysis of 9,401 pancreas transplants performed in the US between 2000 and 2006 [46] . The PDRI is a continuous scale that can be used in the assessment of the differential impact of organ quality on the outcomes of pancreas transplants, as well as to account for interactions between relevant factors. A significant, graded reduction in the 1-year pancreas graft survival rate for all types of pancreas transplants was associated with increasing PDRI. It is noteworthy that for given PDRI values, there were significant geographic variations in pancreas utilization. The disparity in overall utilization of pancreas donors with a PDRI of 1.16-1.56 varied from a high of 83 % in one UNOS region to a low of 38 % in another region. Higher PDRI values were also correlated with increasing center activity. The 75th percentile PDRI among transplant centers performing <10 SPKTs over 2.5 years was 1.19 compared with 1.42 for centers performing >40 SPKTs over 2.5 years. Based on this analysis and using data available at the time of organ offer, it was concluded that the PDRI could predict pancreas transplant graft outcome. It is a measure of graft quality that could be utilized in the enhancement of the efficiency of the organ allocation process. This could potentially allow higher-risk organs to be used more effectively in appropriate clinical settings. The average annual PDRI for transplanted pancreata in the US has been steadily decreasing (from a mean of 1.3 to 1.1) over the past decade. Overall reductions in cold ischemia that lower the PDRI score account in large part for this phenomenon [4••] .
Intra-Operative Assessment of the Pancreas Allograft
The appearance of the organ at the time of procurement is the best indication of suitability for transplantation in a pancreas allograft. It is critical that the procuring surgeon be well versed in proper procurement techniques so that there is minimal handling of the pancreas and that the recipient surgeon is be provided with an accurate description of the quality of the vasculature, presence or absence of graft edema or fibrosis, and fat content. The inspection of the organ by an experienced pancreas transplant surgeon is one of the most important determinants of pancreas suitability. This is best achieved by using the spleen as a handle, thus allowing the complete mobilization of the tail and body of the pancreas up into the operative field. Most surgeons avoid transplanting organs with calcifications, severe edema, fatty infiltration, extensive fibrosis, or significant visceral atherosclerosis. The presence of a firm, hard, or 'woody' texture may indicate the presence of pre-existing parenchymal disease; therefore it is also important that the surgeon carefully notes the texture of the gland. Albeit subjective, these criteria are superior to the decision of rejecting organs based only on demographic and laboratory data, and sight unseen at that. Some studies suggest that pancreas utilization could be improved by restricting pancreas recovery to those centers that are actively performing and experienced in pancreas transplantation [12, 45] .
While the procurement of the pancreas itself is an important part of the transplantation process, the success of the transplant procedure relies on proper back table reconstruction of the arterial vasculature. This is usually done using a donor iliac or carotid artery Y graft [5••, 32] . Damage to these vessels stemming from the failure to identify atherosclerotic vascular disease, or surgical damage to these vessels from improper technique or traction injuries, may significantly jeopardize the outcome of the operation; therefore, they should be procured only by an experienced surgeon.
Anatomical Variations/Recovery Techniques
The majority of pancreas donors are also liver donors, which underscores the fact that the vasculature must be shared between these two organs. This creates yet another challenge for the transplant surgeon. From an arterial anatomy point of view, the splenic artery (SA) and superior mesenteric artery (SMA) are routinely preserved with the pancreas allograft, with ligation of the gastroduodenal artery (GDA). In this way, the hepatic artery (HA) can be preserved intact with the liver allograft. The normal anatomy (86 %) involves a bifurcation of the celiac axis trunk into the HA, left gastric artery, and SA [56] . In 10-17 % of donors, there will be an accessory right HA arising from the SMA [57] . Depending on the liver transplant center's preference, either a distal cuff of SMA may be retained along with the right HA for back table reconstruction of the liver with a short stump of the SMA preserved with the pancreas [58] , or the accessory right HA itself may be divided and anastomosed to the GDA or SA stump on the back bench, leaving the entire SMA with the pancreas allograft [59] . It may be preferable to remove the liver and pancreas en bloc, with subsequent separation of the organs and division of the vessels on the back bench when an accessory right HA is identified. All of these variations are compatible with safe procurement of both the pancreas and the liver, given that there is careful attention to detail, as long as the SA and SMA are preserved with the pancreas allograft. Reconstruction of the GDA or gastro-epiploic artery may be performed to improve perfusion to the head of the pancreas and duodenum, in the case of an extremely short SMA stump [60] [61] [62] , particularly in the absence of cross-circulation between the SA and SMA (which may be assessed by flushing the SA and looking for back-flushing through the SMA or vice versa).
There is little variation, generally speaking, in the portal venous anatomy, other than the location of the coronary (left gastric) vein and the inferior mesenteric vein. The portal vein arises from the confluence of the superior mesenteric vein (SMV) and splenic vein and forms a single large vein supplying the liver. An appropriate length of portal vein is required for both the pancreas and the liver allografts. From a pancreas perspective, it is preferable if the portal vein is transected halfway between the superior border of the pancreas and the inferior border of the liver. As long as the venous confluence is intact, however, the pancreas can usually be transplanted. Most recovery surgeons transect the portal vein adjacent to the coronary vein, but in some cases, the coronary vein may be in proximity to the SMV and splenic vein confluence. Donor iliac vein may be required for venous reconstruction of the portal vein stump of the pancreas graft if this anatomic variant is not recognized; this dependent on the venous anatomy in the recipient.
The mesentery of the small bowel must be divided in situations where a multi-organ donor will be donating a pancreas and a solitary intestinal allograft, thus preserving the proximal SMA and SMV with their pancreatic branches to the head of the pancreas as well as to the duodenum, with the pancreas allograft and the more distal SMA and SMV along with the most proximal jejunal branches, with the intestinal graft [63, 64] . A useful way to achieve this desired outcome, at the time of procurement, is to perform a total abdominal colectomy and to follow the middle colic artery proximally to its origin from the SMA. This usually delineates the ideal site for transection. Dissection of the SMV is performed distally to the point where there is only a single branch. Cases where the same donor has provided both isolated pancreas and small intestine grafts have met with some success; however, this appears to work best when both organs are procured and transplanted at the same center.
Because of concerns over a short mesenteric root leading to compromise of the inferior pancreaticoduodenal vascular arcade, some centers consider small intestinal recovery to be a relative if not absolute contraindication to pancreas procurement. The reality is that in most circumstances both the intestine and the pancreas can be safely procured and transplanted from a single donor, but it is strongly recommended that an experienced pancreas recovery surgeon participate in the retrieval operation [58, 63, 64] .
Pancreas Preservation
The standard preservation solution used for abdominal organ transplantation at most centers is currently University of Wisconsin (UW) solution [65] . For abdominal organ transplantation, however, Histidine-Tryptophan Ketoglutarate (HTK) solution is increasingly being used [65] [66] [67] [68] [69] [70] [71] [72] [73] . The lower viscosity, reduced potassium, and lower cost are cited as the advantages of this solution. Some evidence suggests that pancreas preservation with HTK solution may be associated with a higher incidence of early graft loss and allograft pancreatitis. These effects, however, are mitigated by reducing pancreas cold ischemia to 12 hours or less and by limiting the in situ aortic flush volumes to 3-4 liters. Additional flushing of the pancreas ex vivo is probably not necessary, as opposed to the requirements of the kidney and liver, and may be harmful to the microcirculation of the pancreas. Because it is difficult to exsanguinate the spleen, using clearance of the portal venous effluent to determine volume of flush is not an advisable procedure for the pancreas. Independent of method of pancreas preservation or donor criteria, a number of studies have demonstrated that keeping pancreas cold ischemia below 12 hours is associated with lower rates of allograft pancreatitis, thrombosis, or early graft loss [66] [67] [68] .
Barriers to Expanding the Pancreas Donor Pool
In an ideal situation, the final decision to accept a pancreas allograft for transplantation would be deferred until after visualization at the donor recovery site and after the transplanting surgeon has had an opportunity to examine the organ on the back bench. Frequently, however, there are other mitigating factors and policies that interfere with this sequence of events. For example, according to a Medicare ruling (CMS-1543-R), all of the costs associated with evaluating an organ donor must be equally distributed amongst all of the organs intended for transplantation regardless of which organs are ultimately recovered and transplanted. Although not the primary goal of this policy, this disincentivizes OPOs from attempting to aggressively allocate more pancreata from expanded criteria donors. Pursuing organs that are likely to be declined drives up the cost of these organs because the cost of the donor evaluation and management is increased yet, by not performing the actual transplant, the OPO does not receive full reimbursement for costs accrued. To offset this lack of reimbursement, some OPOs will increase their organ acquisition charge for non-renal organs, while others will operate with a net loss for pancreas and other organs as long as the organization as a whole is not losing money. Another major barrier to expanding the donor pool is the concept of accepting organs on 'waivers.' Although not well described, many programs request anatomical or crossmatch waivers from the host OPO prior to accepting an import organ. There is certainly opportunity for abuse of this policy; for example, by importing organs with no intention of transplanting most of them. It is, however, very difficult for a transplant surgeon to take a risk on a donor pancreas without independently evaluating it on the back bench, particularly when it is retrieved by an unfamiliar team. This problem is magnified when the procuring team is inexperienced or in training. It seems appropriate that if there are technical issues with the recovery or anatomical details that were never relayed to the receiving surgeon when describing the organ, then organ acceptance on waivers would not be required for the OPO to accept responsibility for the organ costs. Finally, one of the most potent barriers to innovation and expanding boundaries in pancreas transplantation are regulatory systems such as the program-specific reports generated by SRTR [74, 75] . The outcomes of these reports are frequently scrutinized for lack of a commonly accepted definition of pancreas graft failure and for poor risk adjustment, including inadequate characterization of both donor and recipient risk factors. As these reports are widely available, many programs find themselves unwilling to take any risk that may jeopardize outcomes, even though that results in longer waiting times or candidates dying on the waitlist. As a transplant community, if our goal is to offer the option of transplantation to as many appropriate recipients as possible, then we are going to have to work collaboratively in order to remove or overcome some of these unintentional barriers to expanding the donor pool.
Conclusions
Pancreas graft acceptance is more selective, pancreas donor and graft evaluation are less precise, and pancreas organ recovery is more challenging than the recovery of other solid organs. Appropriate donor selection, organ recovery, management, and the minimization of cold ischemia are widely accepted as keys to pancreas transplantation success. The pancreas allograft is a scarce resource that is currently underutilized.
It is critical that every effort be expended, so that all potential recipients on the pancreas waiting list can be transplanted in a timely manner; this while continuing to optimize the outcomes from this very challenging procedure, both for the donor and the recipient.
In order to minimize morbidity and graft loss, there are multiplicities of factors that must be well thought-out during evaluation of the potential pancreas allograft donor. There are still transplantable organs that are not being used to full effect, even today. Without doubt, every transplant surgeon should be aware of his or her own limitations and, as well, be wholly familiar with their waiting list. Liberalization of donor criteria appears to be more appropriate in SPKT. With increased experience, it may be both prudent and practical to await visualization before one excludes an organ from transplantation based solely on donor history or other, non-visual criteria. If the donor is overweight, has a cerebrovascular cause of death, is older (>45 years), or DCD, then it would probably be desirable to consider the pancreas exclusively for SPKT, only if all other variables are ideal and then, only if it is possible to minimize cold ischemia to <12 hours.
